FDA-Funded Clinical Trial: Kratom Leaf Powder Safe and Well-Tolerated at Tested Doses

Why it matters

The largest controlled kratom administration study ever conducted—funded by the FDA itself—found no serious adverse events and no evidence of meaningful abuse potential or withdrawal. This gold-standard clinical data directly contradicts calls for federal scheduling and provides scientific support for evidence-based regulation rather than prohibition.

The big picture

For over a decade, federal agencies have cited the lack of controlled human safety data as a reason to consider kratom dangerous. A randomized, double-blind, placebo-controlled trial of 116 healthy adults over 47 days, conducted with FDA funding and published in Therapeutic Drug Monitoring (January 2026), demonstrated that whole-leaf kratom powder was "safe and well tolerated" with no serious adverse events. The study tested four escalating dose levels of MitraLeaf kratom powder and found side effects were dose-dependent, mild in severity, and consistent with consumer reports.

Key findings

• No serious adverse events or deaths in active kratom group or placebo group; most common side effects (nausea, dizziness, headache) were mild and dose-dependent; no clinically significant abnormalities in vital signs, respiratory function, or ECG; no evidence of meaningful abuse potential or withdrawal during 47-day study window; some participants showed reversible liver enzyme elevations, particularly at highest dose (53.2 mg mitragynine), but no cases met Hy's Law criteria for serious drug-induced liver injury; peak plasma concentrations reached 1-2 hours after dosing; study represents gold standard in clinical safety research—the type that regulatory bodies had previously cited as lacking.

What they say

According to the published study: "At the tested doses, kratom leaf powder was safe and well tolerated, with no serious adverse events, no deaths, and no evidence of meaningful abuse potential or withdrawal." The study's conclusion directly supports evidence-based regulation over prohibition, strengthening the scientific case for the Kratom Consumer Protection Act framework adopted in multiple states.

Bottom line

**The FDA-funded clinical trial showing kratom's safety profile at reasonable doses fundamentally shifts the regulatory conversation from whether kratom should exist to how it should be responsibly regulated—a framework that over 20 states have already adopted.**